News & Updates

The combination of re-cellularization via electroporation therapy (ReCET) plus semaglutide appears to improve glucose control and metabolic health and eliminate the need for insulin therapy in most patients with type 2 diabetes (T2D), with the effects maintained up to 2 years, according to the follow-up data from the single-arm, dose-finding, first-in-human EMINENT trial.

Patients with primary cutaneous B-cell lymphoma (PCBCL) treated with ultra-low dose external beam radiation therapy (EBRT) to 4 Gy total dose in two fractions experience durable local control without skin toxicity, reports a study.

In Singapore, influenza and pneumococcal vaccination coverage remains stubbornly low. Results of two separate analysis of a cross-sectional survey shed light on this concerning trend, highlighting the roles of vaccine knowledge and attitude, healthcare professionals, and social support in influencing vaccination decisions.

The novel plant-based polyphenol-rich compound, TOTUM-63, helps keep the lid on fasting plasma glucose (FPG) and other measures of glucose dysregulation in people with prediabetes and early type 2 diabetes (T2D), according to the pivotal phase II/III REVERSE-IT study.